Financhill
Sell
8

CLRB Quote, Financials, Valuation and Earnings

Last price:
$4.97
Seasonality move :
-13.76%
Day range:
$4.80 - $5.05
52-week range:
$4.36 - $94.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
137.94x
P/B ratio:
1.14x
Volume:
61.7K
Avg. volume:
901.5K
1-year change:
-93.41%
Market cap:
$8.8M
Revenue:
--
EPS (TTM):
-$21.90

Earnings Data

Next earnings date for CLRB
Aug 13
2025
Most recent earnings per share
-$4.20
Beat by $0.70
(May 13/2025)
Consensus Estimate
-$4.90
(May 13/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

CLRB Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
09/30/2025 Q3 -- -- -- -$3.60 --
08/13/2025 Q2 -- -- -- -$3.70 --
05/13/2025 Q1 -- -- -$4.20 -$4.90 $0.70
03/13/2025 Q4 -- -- -$0.30 -$10.58 $10.28
11/18/2024 Q3 -- -- -$12.00 -$11.20 -$0.80
08/13/2024 Q2 -- -- -$5.40 -$8.10 $2.70
05/14/2024 Q1 -- -- -$27.30 -$16.90 -$10.40
03/27/2024 Q4 -- -- -$12.30 -$15.90 $3.60
11/02/2023 Q3 -- -- -$46.50 -$13.35 -$33.15
08/04/2023 Q2 -- -- -$27.00 -$19.95 -$7.05
05/10/2023 Q1 -- -- -$19.20 -- --
03/21/2023 Q4 -- -- -$30.30 -- --
11/08/2022 Q3 -- -- -$38.40 -- --
08/05/2022 Q2 -- -- -$36.60 -- --
05/10/2022 Q1 -- -- -$30.00 -- --
03/02/2022 Q4 -- -- -$28.80 -- --
11/08/2021 Q3 -- -- -$29.10 -- --
08/09/2021 Q2 -- -- -$34.20 -- --
05/10/2021 Q1 -- -- -$39.00 -- --
03/02/2021 Q4 -- -- -$21.00 -- --
11/09/2020 Q3 -- -- -$45.00 -- --
08/10/2020 Q2 -- -- -$78.00 -- --
03/31/2020 Q1 -- -- -$126.00 -- --
12/31/2019 Q4 -- -- -$99.00 -- --
09/30/2019 Q3 -- -- -$126.00 -- --
06/30/2019 Q2 -- -- -$138.00 -- --
03/31/2019 Q1 -- -- -$228.00 -- --
12/31/2018 Q4 -- -- -$242.65 -- --
09/30/2018 Q3 -- -- -$495.00 -- --
06/30/2018 Q2 -- -- -$507.00 -- --
03/31/2018 Q1 -- -- -$621.00 -- --
12/31/2017 Q4 -- -- -$1,020.00 -- --
09/30/2017 Q3 -- -- -$774.00 -- --
06/30/2017 Q2 -- -- -$696.00 -- --
03/31/2017 Q1 -- -- -$720.00 -- --
03/15/2017 Q4 -- -- -$1,668.14 -- --
11/11/2016 Q3 -- -- -$1,290.00 -- --
08/15/2016 Q2 -- -- -$1,470.00 -- --
05/12/2016 Q1 -- -- $2,883.09 -- --
03/10/2016 Q4 -- -- $3,324.87 -- --
11/12/2015 Q3 -- -- -$7,373.96 -- --

Cellectar Biosciences Earnings Questions

  • How Much did Cellectar Biosciences Generate in Revenue Last Quarter?

    Cellectar Biosciences reported -- worth of top line sales in its most recent quarter.

  • Did Cellectar Biosciences Beat Earnings Last Quarter?

    Cellectar Biosciences announced earnings per share of -$4.20 which represents a beat of analyst forecast a -$4.90 per share.

  • Is Cellectar Biosciences Profitable?

    Cellectar Biosciences reported -- that represents -- per share over the last quarter.

  • What is the Analyst Consensus for Cellectar Biosciences EPS Next Year?

    Cellectar Biosciences's earnings are forecast to decrease from -$42.00 per share to -$47.03 per share next year representing a decrease of -63.33%.

  • When is Cellectar Biosciences's Earnings Date?

    Cellectar Biosciences's next earnings date is August 13, 2025.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 14

MiNK Therapeutics [INKT] is down 36.03% over the past day.

Buy
51
NEGG alert for Jul 14

Newegg Commerce [NEGG] is down 26.42% over the past day.

Buy
68
ATRO alert for Jul 14

Astronics [ATRO] is down 1.02% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock